|
Novelty in the hormonal treatment of the cancer of the prostate
Tuesday August 12, 2008 The cancer of the prostate is the first at the man of more than 50 years. In the setting of the treatment to an advanced stage, the only opportunity often resides in the control of the testosterone rate via the hormonotherapy. New ways to take in charge the illness appear, structural less prejudice to the patients. The carcinomas of the prostate are said "hormono-dependent": the tumors react to the testosterone that the "booste." In the case of a cancer of the prostate to an advanced stage, the only manner to suppress this influx of testosterone is the castration. The patient has the choice between two principles: surgical or chemical via the hormonotherapy. The first, traumatic for the patient, is more and more abandoned to the profit of the second, making themselves by the injection of synthesis hormones.
Only, this last method requires multiple injections: as many recalls of his illness for the patient. The laboratory Astellas Pharma developed a new treatment, Eligard ®, only requiring an injection every 6 months. This spacing offers to the patient a perception more positive of his health state from afar with a stake of the illness.
A problematic important, when one knows that, because of the precocious tracking of the illness, the men will be brought to live longer with a treatment.
|
